Guggenheim Sees Upside In Aegerion (AEGR); AVEO Pharma (AVEO) Inks Mega-Deal


Brokerage firm Guggenheim has changed its view drastically on Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) and upgraded the company’s stock from a Sell to a Buy rating with a price target of $13.00, sending its shares up in pre-market trading Monday.

AEGR stock closed at $9.01, up $0.06 (or +0.67%), with a total volume of 4,735,181 shares traded on Friday, a large increase in activity versus its average volume (3m) of 876,052

Aegerion Pharmaceuticals, a biopharmaceutical company, has 28.94M Shares Outstanding, Market Capitalization (intraday) of $260.73M and AEGR stock 52-week range is between $8.68 and $28.97 per share



Shares of AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) climbed more than 15% before the opening bell on Monday as the company said that it has granted EUSA Pharma European rights to its lead investigational drug tivozanib. As part of the deal,  EUSA Pharma will pay $2.5 million upfront research payment and up to $394 million in milestones payments to AVEO.

AVEO stock finished at $1.03, down $0.06 (or -5.50%) on Friday’s tradingg session, and 615,660 of its shares exchanged hands during the day

AVEO Pharmaceuticals, a biopharmaceutical company, has 58.18M Shares Outstanding and AVEO stock one year range is from $0.75 to $3.50 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at